What’s new in the PerkinElmer reagent portfolio ?
New products using the HTRF® technology
The Biomarkers assays portfolio is enriched with 5 new kits !
- ApoE Human Kit
- Estrogen Receptor Human Kit
- Human and Mouse Fibronectin Kit
- Human Fibronectin-EDA Kit
- TYK2 Total Kit
In addition, 2 assays have been added to the Cellular Phospho-Protein assays portfolio and 2 other assays to the Protein-Protein Interactions assays portfolio !
Targeted Protein Degradation portfolio has been enriched with two new kits:
New products using the AlphaLISA® technology
In the Biomarkers assays portfolio:
The Protein-Protein Interactions assays portfolio have been enriched with two forms of an attractive target in cancer therapies: the X-linked inhibitor of apoptosis protein.
The complement factor C1Q is now available in the innate immunity portfolio:
New products using the AlphaLISA® SureFire® Ultra™ technology
And, finally, 9 new assays were added to the Cellular Phospho-Protein assays portfolio !
For all the Alpha® products, please contact your local representatives or visit www.perkinelmer.com